BRPI0812904A2 - COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA - Google Patents

COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA

Info

Publication number: BRPI0812904A2
Authority: BR; Brazil
Prior art keywords: cortisol; inhibition; same; spyrocycles; 11ßhsd1
Prior art date: 2007-06-21

Application number

BRPI0812904-5A2A

Other languages

English (en)

Inventor

Wenqing Yao

Jincong Zhuo

Colin Zhang

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-21

Filing date

2008-06-20

Publication date

2014-12-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812904(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-20 Application filed by Incyte Corp filed Critical Incyte Corp

2014-12-09 Publication of BRPI0812904A2 publication Critical patent/BRPI0812904A2/pt

Links

JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title 6
229960000890 hydrocortisone Drugs 0.000 title 3
230000005764 inhibitory process Effects 0.000 title 2
238000006243 chemical reaction Methods 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0812904-5A2A 2007-06-21 2008-06-20 COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA BRPI0812904A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94548707P	2007-06-21	2007-06-21
PCT/US2008/067637 WO2008157752A1 (en)	2007-06-21	2008-06-20	Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1

Publications (1)

Publication Number	Publication Date
BRPI0812904A2 true BRPI0812904A2 (pt)	2014-12-09

Family

ID=39731144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812904-5A2A BRPI0812904A2 (pt)	2007-06-21	2008-06-20	COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA

Country Status (30)

Country	Link
US (4)	US8278318B2 (pt)
EP (3)	EP2173750B9 (pt)
JP (2)	JP5364702B2 (pt)
KR (1)	KR101554471B1 (pt)
CN (1)	CN101815716B (pt)
AR (1)	AR067090A1 (pt)
AU (1)	AU2008265656B2 (pt)
BR (1)	BRPI0812904A2 (pt)
CA (1)	CA2691150C (pt)
CL (1)	CL2008001839A1 (pt)
CO (1)	CO6150151A2 (pt)
CR (1)	CR11183A (pt)
CY (2)	CY1113212T1 (pt)
DK (2)	DK2173750T3 (pt)
EA (1)	EA016017B1 (pt)
EC (1)	ECSP109844A (pt)
ES (2)	ES2390937T3 (pt)
GE (1)	GEP20135754B (pt)
HR (2)	HRP20120772T1 (pt)
IL (1)	IL202842A (pt)
MX (1)	MX2009014274A (pt)
NZ (1)	NZ582524A (pt)
PL (2)	PL2540723T3 (pt)
PT (2)	PT2540723E (pt)
RS (2)	RS52519B9 (pt)
SI (2)	SI2173750T1 (pt)
TW (1)	TWI428340B (pt)
UA (1)	UA98651C2 (pt)
WO (1)	WO2008157752A1 (pt)
ZA (1)	ZA201000233B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
WO2006002350A1 (en) *	2004-06-24	2006-01-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
CA2584502A1 (en) *	2004-06-24	2006-01-05	Incyte Corporation	2-methylpropanamides and their use as pharmaceuticals
US8071624B2 (en)	2004-06-24	2011-12-06	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
CA2571258A1 (en) *	2004-06-24	2006-01-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
AU2005273986A1 (en) *	2004-08-10	2006-02-23	Incyte Corporation	Amido compounds and their use as pharmaceuticals
US8110581B2 (en) *	2004-11-10	2012-02-07	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
US20070213311A1 (en) *	2006-03-02	2007-09-13	Yun-Long Li	Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EA014718B1 (ru)	2006-04-21	2011-02-28	Эли Лилли Энд Компани	Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
AU2007240450B2 (en)	2006-04-21	2011-12-22	Eli Lilly And Company	Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5161869B2 (ja)	2006-04-21	2013-03-13	イーライリリーアンドカンパニー	１１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としての、シクロヘキシルピラゾール−ラクタム誘導体
EA016415B1 (ru)	2006-04-24	2012-04-30	Эли Лилли Энд Компани	Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CN101432263B (zh)	2006-04-24	2012-03-07	伊莱利利公司	作为11-β-羟类固醇脱氢酶1抑制剂的取代的吡咯烷酮类
JP5269765B2 (ja)	2006-04-24	2013-08-21	イーライリリーアンドカンパニー	１１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
CN101432265B (zh)	2006-04-25	2011-12-14	伊莱利利公司	11-β-羟类固醇脱氢酶1的抑制剂
DK2021337T3 (da)	2006-04-25	2010-03-29	Lilly Co Eli	Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
JP5101602B2 (ja)	2006-04-25	2012-12-19	イーライリリーアンドカンパニー	１１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
DK2049513T3 (da)	2006-04-28	2012-02-27	Lilly Co Eli	Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
EP2018378A2 (en) *	2006-05-17	2009-01-28	Incyte Corporation	Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
CL2008001839A1 (es)	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
AR074466A1 (es)	2008-12-05	2011-01-19	Sanofi Aventis	Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
EP2243479A3 (en)	2009-04-20	2011-01-19	Abbott Laboratories	Novel amide and amidine derivates and uses thereof
WO2011068927A2 (en) *	2009-12-04	2011-06-09	Abbott Laboratories	11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3105218B1 (en)	2014-02-13	2019-09-25	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
EP3105219B9 (en)	2014-02-13	2018-10-03	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
JP6602779B2 (ja)	2014-02-13	2019-11-06	インサイト・コーポレイション	Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en)	2014-07-10	2017-09-12	Incyte Corporation	Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695180B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyridines and imidazopyrazines as lsd1 inhibitors
EP3277689B1 (en)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
MY189367A (en)	2015-08-12	2022-02-08	Incyte Corp	Salts of an lsd1 inhibitor
EP3235813A1 (en)	2016-04-19	2017-10-25	Cidqo 2012, S.L.	Aza-tetra-cyclo derivatives
TWI833686B (zh)	2016-04-22	2024-03-01	美商英塞特公司	Lsd1 抑制劑之調配物
US10435841B2 (en) *	2016-05-03	2019-10-08	GranBio Intellectual Property Holdings, LLC	Nanocellulose-reinforced corrugated medium
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4439606A (en) *	1982-05-06	1984-03-27	American Cyanamid Company	Antiatherosclerotic 1-piperazinecarbonyl compounds
US5206240A (en) *	1989-12-08	1993-04-27	Merck & Co., Inc.	Nitrogen-containing spirocycles
US5852029A (en) *	1990-04-10	1998-12-22	Israel Institute For Biological Research	Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5102886A (en)	1990-10-12	1992-04-07	American Home Products Corporation	1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
DE4234295A1 (de) *	1992-10-12	1994-04-14	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) *	1993-05-17	1995-07-21	Fournier Ind & Sante	Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) *	1994-09-15	1996-12-13	Adir	Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734265B1 (fr)	1995-05-17	1997-06-13	Adir	Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2736053B1 (fr) *	1995-06-28	1997-09-19	Sanofi Sa	Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
WO1997011940A1 (en)	1995-09-29	1997-04-03	Eli Lilly And Company	Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
ATE250604T1 (de)	1999-10-27	2003-10-15	Millennium Pharm Inc	Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
EP1236726B1 (en) *	1999-12-03	2004-12-01	Ono Pharmaceutical Co., Ltd.	Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient
KR100786927B1 (ko)	2000-06-28	2007-12-17	스미스클라인비이참피이엘시이	습식 분쇄방법
US7294637B2 (en) *	2000-09-11	2007-11-13	Sepracor, Inc.	Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
WO2003000657A1 (en) *	2001-06-20	2003-01-03	Daiichi Pharmaceutical Co., Ltd.	Diamine derivatives
US6547958B1 (en) *	2001-07-13	2003-04-15	Chevron U.S.A. Inc.	Hydrocarbon conversion using zeolite SSZ-59
GB0118238D0 (en)	2001-07-26	2001-09-19	Smithkline Beecham Plc	Medicaments
GB0126292D0 (en)	2001-11-01	2002-01-02	Smithkline Beecham Plc	Compounds
WO2003057698A2 (en)	2001-12-28	2003-07-17	Acadia Pharmaceuticals, Inc.	Spiroazacyclic compounds as monoamine receptor modulators
US6818772B2 (en) *	2002-02-22	2004-11-16	Abbott Laboratories	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
GB0213715D0 (en) *	2002-06-14	2002-07-24	Syngenta Ltd	Chemical compounds
EP1553098A1 (en) *	2002-10-18	2005-07-13	Ono Pharmaceutical Co., Ltd.	Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
WO2004058727A1 (en)	2002-12-20	2004-07-15	Bayer Pharmaceuticals Corporation	Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004056744A1 (en)	2002-12-23	2004-07-08	Janssen Pharmaceutica N.V.	Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en)	2003-01-24	2005-02-01	Novartis Ag	Organic compounds
US7205318B2 (en)	2003-03-18	2007-04-17	Bristol-Myers Squibb Company	Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
ATE482747T1 (de)	2003-04-11	2010-10-15	High Point Pharmaceuticals Llc	Neue amide derivate und deren pharmazeutische verwendungen
JPWO2005047286A1 (ja)	2003-11-13	2007-05-31	小野薬品工業株式会社	スピロ複素環化合物
EP1696915A1 (en)	2003-12-19	2006-09-06	Pfizer, Inc.	Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
JP2007516298A (ja)	2003-12-23	2007-06-21	アリーナファーマシューティカルズ，インコーポレイテッド	新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
US7435830B2 (en)	2004-03-03	2008-10-14	Chemocentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
JP2007536369A (ja)	2004-05-06	2007-12-13	ファイザー・インク	プロリン及びモルホリン誘導体の新規化合物
TWI350168B (en) *	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
CA2571258A1 (en) *	2004-06-24	2006-01-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
US20050288317A1 (en) *	2004-06-24	2005-12-29	Wenqing Yao	Amido compounds and their use as pharmaceuticals
WO2006012227A2 (en)	2004-06-24	2006-02-02	Incyte Corporation	Amido compounds and their use as pharmaceuticals
CA2584502A1 (en)	2004-06-24	2006-01-05	Incyte Corporation	2-methylpropanamides and their use as pharmaceuticals
WO2006002350A1 (en) *	2004-06-24	2006-01-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
US8071624B2 (en)	2004-06-24	2011-12-06	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
CA2571361C (en)	2004-06-28	2011-07-26	F. Hoffmann-La Roche Ag	Pyrimidine derivatives as 11beta-hsd1 inhibitors
AU2005273986A1 (en)	2004-08-10	2006-02-23	Incyte Corporation	Amido compounds and their use as pharmaceuticals
NZ553849A (en)	2004-09-29	2010-04-30	Hoffmann La Roche	Indozolone derivatives as 11B-HSD1 inhibitors
DE602005027230D1 (de)	2004-10-22	2011-05-12	Merck Sharp & Dohme	Cgrp-rezeptorantagonisten
ES2547724T3 (es)	2004-11-10	2015-10-08	Incyte Corporation	Compuestos de lactama y su uso como productos farmacéuticos
US7505739B2 (en) *	2004-11-12	2009-03-17	Atheros Technology Ltd.	Automatic mode setting and power ramp compensator for system power on conditions
CN101103016A (zh) *	2004-11-18	2008-01-09	因塞特公司	11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
CN101142172A (zh) *	2005-01-05	2008-03-12	艾博特公司	11-β-羟甾类脱氢酶1型酶的抑制剂
EP1866285A1 (en) *	2005-03-03	2007-12-19	F. Hoffmann-Roche AG	1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
CA2621255A1 (en) *	2005-09-21	2007-04-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
EP1940842B1 (en)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AR057579A1 (es)	2005-11-23	2007-12-05	Merck & Co Inc	Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
CA2630492C (en) *	2005-12-05	2015-04-14	Incyte Corporation	Spiro-lactam compounds
WO2007084314A2 (en) *	2006-01-12	2007-07-26	Incyte Corporation	MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
AU2007210018A1 (en) *	2006-01-31	2007-08-09	Incyte Corporation	Amido compounds and their use as pharmaceuticals
US20070213311A1 (en) *	2006-03-02	2007-09-13	Yun-Long Li	Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) *	2006-03-03	2007-09-13	Incyte Corporation	MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
JP2009535420A (ja) *	2006-05-01	2009-10-01	インサイト・コーポレイション	１１−βヒドロキシルステロイドデヒドロゲナーゼタイプ１のモジュレーターとしてのテトラ置換ウレア
EP2018378A2 (en) *	2006-05-17	2009-01-28	Incyte Corporation	Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
AU2007271273B2 (en)	2006-07-05	2011-09-01	F. Hoffmann-La Roche Ag	Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11B-HSD 1)
CN101553474B (zh)	2006-10-19	2013-02-27	霍夫曼-拉罗奇有限公司	作为糖尿病用11b-HSD1抑制剂的咪唑啉酮和咪唑烷酮衍生物
CL2008001839A1 (es)	2007-06-21	2009-01-16	Incyte Holdings Corp	Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

2008
- 2008-06-19 CL CL2008001839A patent/CL2008001839A1/es unknown
- 2008-06-20 PT PT12178110T patent/PT2540723E/pt unknown
- 2008-06-20 EP EP08771573.6A patent/EP2173750B9/en active Active
- 2008-06-20 SI SI200830779T patent/SI2173750T1/sl unknown
- 2008-06-20 US US12/143,427 patent/US8278318B2/en active Active
- 2008-06-20 TW TW097123261A patent/TWI428340B/zh not_active IP Right Cessation
- 2008-06-20 CA CA2691150A patent/CA2691150C/en active Active
- 2008-06-20 ES ES08771573T patent/ES2390937T3/es active Active
- 2008-06-20 PT PT08771573T patent/PT2173750E/pt unknown
- 2008-06-20 RS RS20120423A patent/RS52519B9/sr unknown
- 2008-06-20 EP EP14193608.8A patent/EP2918586A1/en not_active Withdrawn
- 2008-06-20 RS RS20150103A patent/RS53839B1/sr unknown
- 2008-06-20 WO PCT/US2008/067637 patent/WO2008157752A1/en not_active Ceased
- 2008-06-20 DK DK08771573.6T patent/DK2173750T3/da active
- 2008-06-20 PL PL12178110T patent/PL2540723T3/pl unknown
- 2008-06-20 GE GEAP200811654A patent/GEP20135754B/en unknown
- 2008-06-20 NZ NZ582524A patent/NZ582524A/en unknown
- 2008-06-20 DK DK12178110.8T patent/DK2540723T3/en active
- 2008-06-20 JP JP2010513441A patent/JP5364702B2/ja active Active
- 2008-06-20 BR BRPI0812904-5A2A patent/BRPI0812904A2/pt not_active Application Discontinuation
- 2008-06-20 EP EP12178110.8A patent/EP2540723B8/en active Active
- 2008-06-20 KR KR1020107001434A patent/KR101554471B1/ko active Active
- 2008-06-20 PL PL08771573T patent/PL2173750T3/pl unknown
- 2008-06-20 EA EA201070039A patent/EA016017B1/ru unknown
- 2008-06-20 UA UAA201000514A patent/UA98651C2/ru unknown
- 2008-06-20 SI SI200831387T patent/SI2540723T1/sl unknown
- 2008-06-20 AU AU2008265656A patent/AU2008265656B2/en not_active Ceased
- 2008-06-20 HR HRP20120772AT patent/HRP20120772T1/hr unknown
- 2008-06-20 AR ARP080102645A patent/AR067090A1/es active IP Right Grant
- 2008-06-20 MX MX2009014274A patent/MX2009014274A/es active IP Right Grant
- 2008-06-20 ES ES12178110T patent/ES2531056T3/es active Active
- 2008-06-20 CN CN2008801022458A patent/CN101815716B/zh active Active
2009
- 2009-12-20 IL IL202842A patent/IL202842A/en active IP Right Grant
- 2009-12-29 CO CO09148800A patent/CO6150151A2/es unknown
2010
- 2010-01-04 CR CR11183A patent/CR11183A/es unknown
- 2010-01-05 EC EC2010009844A patent/ECSP109844A/es unknown
- 2010-01-12 ZA ZA2010/00233A patent/ZA201000233B/en unknown
2012
- 2012-09-14 US US13/619,160 patent/US9006260B2/en active Active
- 2012-10-17 CY CY20121100974T patent/CY1113212T1/el unknown
2013
- 2013-07-17 JP JP2013148780A patent/JP5730956B2/ja not_active Expired - Fee Related
2015
- 2015-02-18 CY CY20151100167T patent/CY1116029T1/el unknown
- 2015-02-19 HR HRP20150197AT patent/HRP20150197T1/hr unknown
- 2015-04-07 US US14/680,745 patent/US9371323B2/en active Active
2016
- 2016-06-10 US US15/178,838 patent/US9873698B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8278318B2 (en)	2012-10-02
US20130018068A1 (en)	2013-01-17
WO2008157752A1 (en)	2008-12-24
GEP20135754B (en)	2013-02-25
PT2540723E (pt)	2015-03-06
IL202842A (en)	2014-11-30
EP2173750A1 (en)	2010-04-14
EP2540723A1 (en)	2013-01-02
ECSP109844A (es)	2010-02-26
HRP20120772T1 (hr)	2012-10-31
JP5364702B2 (ja)	2013-12-11
JP2010530893A (ja)	2010-09-16
RS52519B9 (sr)	2020-12-31
US9371323B2 (en)	2016-06-21
CN101815716A (zh)	2010-08-25
PT2173750E (pt)	2012-10-11
NZ582524A (en)	2012-05-25
AU2008265656B2 (en)	2014-05-29
IL202842A0 (en)	2010-06-30
CA2691150C (en)	2015-11-24
SI2540723T1 (sl)	2015-04-30
CY1113212T1 (el)	2016-04-13
JP2014015463A (ja)	2014-01-30
ES2531056T3 (es)	2015-03-10
RS53839B1 (sr)	2015-06-30
US20160280708A1 (en)	2016-09-29
CO6150151A2 (es)	2010-04-20
EP2540723B8 (en)	2015-01-28
HRP20150197T1 (en)	2015-03-27
EP2540723B1 (en)	2014-11-26
US9873698B2 (en)	2018-01-23
US9006260B2 (en)	2015-04-14
PL2173750T3 (pl)	2012-12-31
CL2008001839A1 (es)	2009-01-16
ES2390937T3 (es)	2012-11-19
KR101554471B1 (ko)	2015-09-30
SI2173750T1 (sl)	2012-11-30
TW200909431A (en)	2009-03-01
JP5730956B2 (ja)	2015-06-10
HK1143156A1 (en)	2010-12-24
EA201070039A1 (ru)	2010-06-30
AU2008265656A1 (en)	2008-12-24
ZA201000233B (en)	2016-08-31
KR20100045440A (ko)	2010-05-03
CN101815716B (zh)	2012-12-26
MX2009014274A (es)	2010-03-25
US20080318991A1 (en)	2008-12-25
US20150210692A1 (en)	2015-07-30
EP2918586A1 (en)	2015-09-16
DK2540723T3 (en)	2015-01-19
PL2540723T3 (pl)	2015-07-31
EA016017B1 (ru)	2012-01-30
EP2173750B9 (en)	2017-04-05
HK1180325A1 (en)	2013-10-18
CY1116029T1 (el)	2017-01-25
EP2173750B1 (en)	2012-08-01
CA2691150A1 (en)	2008-12-24
DK2173750T3 (da)	2012-11-19
TWI428340B (zh)	2014-03-01
UA98651C2 (ru)	2012-06-11
CR11183A (es)	2010-02-16
RS52519B (sr)	2013-04-30
AR067090A1 (es)	2009-09-30

Legal Events

Date	Code	Title	Description
2015-11-17	B25G	Requested change of headquarter approved	Owner name: INCYTE CORPORATION (US)
2016-08-09	B25A	Requested transfer of rights approved	Owner name: INCYTE HOLDINGS CORPORATION (US)
2018-03-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B11E	Dismissal acc. art. 34 of ipl - requirements for examination incomplete
2020-09-24	B11T	Dismissal of application maintained [chapter 11.20 patent gazette]

Publication	Publication Date	Title
BRPI0812904A2 (pt)	2014-12-09	COMPOSTOS ESPIROCICLOS, COMPOSIÇÃO COMPREENDENDO OS MESMOS, USOS DOS MESMOS, MÉTODOS DE INIBIÇÃO DA ATIVIDADE DE 11ßHSD1, DE INIBIÇÃO DA CONVERSÃO DE CORTISONA EM CORTISOL E DE INIBIÇÃO DA PRODUÇÃO DE CORTISOL EM UMA CÉLULA
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0807146A2 (pt)	2014-04-15	Inibidores da atividade da akt
BRPI1009372A2 (pt)	2016-05-31	compostos, composição farmacêutica e respectivos usos
BRPI1013421A2 (pt)	2016-04-05	composição parasticida tópica, e, uso de uma composição
BRPI1009981A2 (pt)	2016-03-15	sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula
BRPI0918496A2 (pt)	2019-09-24	composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
BR112013013790A2 (pt)	2016-09-13	compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
BRPI1013640A2 (pt)	2019-09-24	composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BR112012003709A2 (pt)	2016-04-05	compostos heterocíclicos e usos dos mesmos
BRPI0822337A2 (pt)	2015-06-16	Folatos, composições e usos dos mesmos
SV2011004019A (es)	2011-12-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI0920927A2 (pt)	2019-09-24	derivados de azaquinolinona e usos dos mesmos
BRPI0924172A2 (pt)	2016-02-10	vitamina d promovendo proteção solar
BRPI0918360A2 (pt)	2017-10-10	composto, composição farmacêutica e usos de um composto
PT2963031T (pt)	2019-03-20	Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI0915897A2 (pt)	2015-11-03	compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
IL214822A0 (en)	2011-11-30	Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
BRPI0908906A2 (pt)	2019-09-24	compostos heterocíclicos e usos dos mesmos
DK2139452T3 (da)	2011-11-14	Topisk polyaphronsammensætning med D-vitamin og corticosteroid
ZA201202489B (en)	2013-02-27	Novel heterocyclic acrylamides and their use as pharmaceuticals
UY33079A (es)	2011-06-01	Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
BR112012001329A2 (pt)	2017-06-13	métodos para obter células com uma potência desejada, para tratar inflamação em um sujeito, para construir um banco de células, para descoberta de droga e para aumentar a potência de uma célula, e, composição.
BRPI0715342A2 (pt)	2015-03-24	Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos
BRPI0818759A2 (pt)	2019-09-24	método para o tratamento de colheitas, solução de pulverização e uso de glicerol bruto derivado da produção de biodiesel na preparação de uma solução de pulverização